Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score.
Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: October 25, 2022
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
Journal: The Journal of infectious diseases
Published: June 27, 2022
Postacute Sequelae of SARS-CoV-2 Infection-Lessons Learned From a Coordinated Health System Response.
Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: June 07, 2022
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Journal: Open forum infectious diseases
Published: June 03, 2022
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Journal: Mayo Clinic proceedings
Published: February 22, 2022
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
Journal: The Journal of infectious diseases
Published: October 05, 2021
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
Journal: Mayo Clinic proceedings
Published: September 01, 2021
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
Journal: EClinicalMedicine
Published: July 05, 2021
Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.
Journal: medRxiv : the preprint server for health sciences
Published: June 02, 2021
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
Journal: Journal of primary care & community health
Published: May 25, 2021
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Journal: The Journal of clinical investigation
Published: May 24, 2021
Last Updated: 09/26/2026